Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.

Hsieh MH, Gu SL, Ho SC, Pawlak CR, Lin CL, Ho YJ, Lai TJ, Wu FY.

Behav Brain Res. 2012 Apr 1;229(1):41-7. doi: 10.1016/j.bbr.2011.12.035. Epub 2012 Jan 2.

PMID:
22227506
[PubMed - indexed for MEDLINE]
2.

Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia.

Ho YJ, Ho SC, Pawlak CR, Yeh KY.

Behav Brain Res. 2011 Jun 1;219(2):280-90. doi: 10.1016/j.bbr.2011.01.028. Epub 2011 Jan 22.

PMID:
21262271
[PubMed - indexed for MEDLINE]
3.

Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats.

Wang AL, Liou YM, Pawlak CR, Ho YJ.

Behav Brain Res. 2010 Mar 17;208(1):38-46. doi: 10.1016/j.bbr.2009.11.006. Epub 2009 Nov 10.

PMID:
19900486
[PubMed - indexed for MEDLINE]
4.

Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model.

Hsieh MH, Ho SC, Yeh KY, Pawlak CR, Chang HM, Ho YJ, Lai TJ, Wu FY.

Pharmacol Biochem Behav. 2012 Jul;102(1):64-71. doi: 10.1016/j.pbb.2012.03.022. Epub 2012 Mar 31.

PMID:
22487770
[PubMed - indexed for MEDLINE]
5.

Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.

Ho SC, Hsu CC, Pawlak CR, Tikhonova MA, Lai TJ, Amstislavskaya TG, Ho YJ.

Behav Brain Res. 2014 Jul 15;268:177-84. doi: 10.1016/j.bbr.2014.04.022. Epub 2014 Apr 19.

PMID:
24755306
[PubMed - in process]
6.

The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.

Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R.

Curr Pharm Des. 2011;17(5):489-507. Review.

PMID:
21375482
[PubMed - indexed for MEDLINE]
7.

MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats.

Wang WF, Wu SL, Liou YM, Wang AL, Pawlak CR, Ho YJ.

Behav Neurosci. 2009 Dec;123(6):1261-70. doi: 10.1037/a0017401.

PMID:
20001109
[PubMed - indexed for MEDLINE]
8.

Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.

Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee KT, Park S.

Neurotox Res. 2009 May;15(4):332-47. doi: 10.1007/s12640-009-9037-x. Epub 2009 Mar 17.

PMID:
19384567
[PubMed - indexed for MEDLINE]
9.

Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.

Monaghan MM, Leddy L, Sung ML, Albinson K, Kubek K, Pangalos MN, Reinhart PH, Zaleska MM, Comery TA.

Neurodegener Dis. 2010;7(1-3):153-9. doi: 10.1159/000289227. Epub 2010 Mar 3.

PMID:
20197696
[PubMed - indexed for MEDLINE]
10.

MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus.

Sy HN, Wu SL, Wang WF, Chen CH, Huang YT, Liou YM, Chiou CS, Pawlak CR, Ho YJ.

Pharmacol Biochem Behav. 2010 Apr;95(2):158-65. doi: 10.1016/j.pbb.2009.12.020. Epub 2010 Jan 11.

PMID:
20064549
[PubMed - indexed for MEDLINE]
11.

Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.

Castro AA, Wiemes BP, Matheus FC, Lapa FR, Viola GG, Santos AR, Tasca CI, Prediger RD.

Brain Res. 2013 Jun 4;1513:103-16. doi: 10.1016/j.brainres.2013.03.029. Epub 2013 Mar 30.

PMID:
23548600
[PubMed - indexed for MEDLINE]
Free Article
12.

Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice.

Deguil J, Chavant F, Lafay-Chebassier C, PĂ©rault-Pochat MC, Fauconneau B, Pain S.

Neurotox Res. 2010 Feb;17(2):142-55. doi: 10.1007/s12640-009-9091-4. Epub 2009 Jul 21.

PMID:
19626386
[PubMed - indexed for MEDLINE]
13.

SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.

Ago Y, Kawasaki T, Nashida T, Ota Y, Cong Y, Kitamoto M, Takahashi T, Takuma K, Matsuda T.

Neuropharmacology. 2011 Dec;61(8):1441-51. doi: 10.1016/j.neuropharm.2011.08.041. Epub 2011 Sep 2.

PMID:
21903118
[PubMed - indexed for MEDLINE]
14.

Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.

Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, Prediger RD.

Behav Brain Res. 2012 Apr 1;229(1):208-15. doi: 10.1016/j.bbr.2012.01.016. Epub 2012 Jan 17.

PMID:
22266923
[PubMed - indexed for MEDLINE]
15.

Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Matheus FC, Aguiar AS Jr, Castro AA, Villarinho JG, Ferreira J, Figueiredo CP, Walz R, Santos AR, Tasca CI, Prediger RD.

Behav Brain Res. 2012 Dec 1;235(2):263-72. doi: 10.1016/j.bbr.2012.08.017. Epub 2012 Aug 17.

PMID:
22921927
[PubMed - indexed for MEDLINE]
16.

Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.

Neurobiol Dis. 2012 Mar;45(3):1051-67. doi: 10.1016/j.nbd.2011.12.024. Epub 2011 Dec 14.

PMID:
22198503
[PubMed - indexed for MEDLINE]
17.

Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.

Novikova L, Garris BL, Garris DR, Lau YS.

Neuroscience. 2006 Jun 19;140(1):67-76. Epub 2006 Mar 14.

PMID:
16533572
[PubMed - indexed for MEDLINE]
18.

The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.

Da Cunha C, Angelucci ME, Canteras NS, Wonnacott S, Takahashi RN.

Cell Mol Neurobiol. 2002 Jun;22(3):227-37. Review.

PMID:
12469866
[PubMed - indexed for MEDLINE]
19.

Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.

Reksidler AB, Lima MM, Dombrowski P, Andersen ML, Zanata SM, Andreatini R, Tufik S, Vital MA.

J Neurosci Methods. 2008 Jan 30;167(2):268-77. Epub 2007 Sep 5.

PMID:
17931705
[PubMed - indexed for MEDLINE]
20.

Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats.

Braga R, Kouzmine I, Canteras NS, Da Cunha C.

Exp Neurol. 2005 Mar;192(1):134-41.

PMID:
15698627
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk